Answer
Linagliptin/metabolites are excreted in animal milk, and risk to a breastfed child cannot be excluded, so a decision must be made whether to stop breastfeeding or discontinue/avoid linagliptin, weighing breastfeeding benefits for the child against treatment benefits for the woman.
Sources for this answer
- Trajenta 5 mg film-coated tabletsBoehringer Ingelheim Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 18Document updated
Sources checked